[Treatment with butyrate/IL-2 combination in peritoneal carcinomatosis of colonic origin].
Two therapeutic assays associating sodium butyrate (NaB) and interleukin-2 (IL-2) were applied on rats after intraperitoneal (i.p.) injection of colon carcinoma cells. The first assay began at day 1 after cell injection, and the second one at day 10 after injection, i.e. when carcinomatosis was established. IL-2 was given i.p. three times per day and NaB one time per day, for five and seven days respectively. The survival median of IL-2 treated rats significantly increased versus those of untreated ones, and was much higher with NaB in supplement. Moreover, using this associative treatment, we observed some cases of complete curacy, even in rats bearing established carcinomatosis.
Perrin
P
P
Laboratoire de Biochimie Médicale, INSERM-CJF 90.11, Institut de Biologie, Nantes, France.
Burg
C
C
Vavasseur
F
F
Galmiche
J P
JP
Bornet
F
F
Meflah
K
K
D000818:Animals; D002087:Butyrates / Q000008:administration & dosage* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary*; D003110:Colonic Neoplasms / Q000473:pathology*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D051381:Rats; D011919:Rats, Inbred Strains; D012964:Sodium / Q000008:administration & dosage / Q000627:therapeutic use
D002087:Butyrates; D007376:Interleukin-2; D012964:Sodium
Traitement par l'association butyrate/IL-2 de carcinoses péritonéales d'origine colique.